Physician profile
Christopher A Davis
NPI 1922196724
$58,340.72
in general payments reported to CMS, 2019-2025
61 companies · $4,972 in 2025
The $4,972 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,981 · 2020: $8,415 · 2021: $6,266 · 2022: $9,552 · 2023: $19K · 2024: $5,877 · 2025: $4,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Long Term Medical Supply Or Device Loan: $3,769 · Education: $81.49 · Travel and Lodging: $56.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,502.72 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,718.13 |
| Long Term Medical Supply Or Device Loan | $3,769.40 |
| Education | $81.49 |
| Travel and Lodging | $56.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13,683.99 | 2022-2024 | Quviviq |
| Abbvie INC. | $7,137.80 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Allergan, INC. | $6,790.92 | 2019-2020 | |
| Horizon Therapeutics Plc | $4,837.55 | 2019-2023 | Tepezza |
| International Rehabilitative Sciences, INC | $4,063.51 | 2021-2025 | Rs 4i Plus Sequential Stimulator, Rs-Lbg Rs-Fbg |
| Astrazeneca Pharmaceuticals Lp | $2,876.75 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,821.28 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,692.83 | 2020-2021 | |
| Lilly USA, LLC | $1,605.60 | 2019-2025 | Mounjaro, Zepbound, Reyvow |
| Amgen INC. | $1,312.12 | 2019-2023 | Repatha |
| Pfizer INC. | $1,275.03 | 2019-2025 | |
| Axsome Therapeutics, INC. | $1,225.60 | 2022-2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $967.17 | 2021-2025 | Rexulti, Abilify Mycite |
| Kowa Pharmaceuticals America, INC. | $886.08 | 2019-2025 | Seglentis, Zoryve, Livalo |
| Amarin Pharma, INC. | $769.96 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.